37 stories mentioning GILDUpdated 8d ago
Every FINWIRES story that references GILD, newest first.
Gilead Sciences (GILD) shares fell 2.6% in afternoon trading on Tuesday after Leerink Partners downgraded the company's stock to market perform from outperform and adjusted the price target to $127 From $146.Trading volume stood at more than 4.3 million shares against a daily average of about 7.5 million.Price: $129.79, Change: $-3.42, Percent Change: -2.57%
Gilead Sciences (GILD) has an average rating of overweight and mean price target of $159.74, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Major US biopharmaceutical companies' performance in the second half of the year is likely to be driven largely by fundamentals, as the focus shifts away from economic factors, Morgan Stanley said in a note e-mailed Wednesday.The investment firm revised its price targets for several biopharma stocks it covers ahead of the latest earnings season."The macro has been a key driver of large-cap biopharma performance over the first half of the year," the brokerage said in a note to clients. "Looking into the second half, we expect fundamentals to be more of a driver. We prefer stocks with upside from product cycles and/or pipeline catalysts."Morgan Stanley raised its price target for Eli Lilly (LLY) to $1,347 from $1,344. It expects second-quarter earnings per share of $9.06 for the pharmaceutical giant, compared with Wall Street's estimate of $8.80. The firm projects revenue of $20.78 billion, while the Street is looking for $20.47 billion.The firm expects Johnson & Johnson (JNJ) to deliver a second-quarter beat, with EPS projected at $2.90 and sales at $25.46 billion. Morgan Stanley raised its price target on the stock to $284 from $283.Pfizer's (PFE) second-quarter EPS is seen at $0.69, while the Street is looking for $0.68, according to the note. Revenue is projected at $14.29 billion, while the Street is eyeing $14.44 billion.Moderna's (MRNA) new price target is $39, up from $33 previously. The drugmaker is expected to report a second-quarter loss of $1.85 a share on revenue of $172 million versus the Street's views for a $2.06 loss and sales of $102 million, according to Morgan Stanley.The price target for the Abbvie (ABBV) stock moved to $279 from $278, with Morgan Stanley expecting the company's second-quarter revenue to be ahead of consensus and guidance at $16.88 billion, while EPS is seen at $3.71 versus the Street's forecast of $3.76.Morgan Stanley lowered its price target for Gilead Sciences (GILD) to $166 from $168. The brokerage is projecting a second-quarter loss per share at $7.34, while the Street is looking for a $7.31 loss. Revenue is expected at $7.36 billion, below the $7.41 billion consensus, according to the note.Price: $1228.54, Change: $-7.02, Percent Change: -0.57%
Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday.As of July 6, the NYSE Arca Pharmaceutical Index has gained 11% and the Nasdaq Biotechnology Index has added 18%, compared with a 10% gain for the S&P 500 Index, with recent stock performance driven more by changes in valuation multiples than by earnings estimate revisions, the investment bank said.Morgan Stanley said its US Equity Strategy team expects the sector to benefit from broader market leadership. Biotech remains one of the most rate-sensitive sectors, and historically, the sector has delivered nearly 20% annualized returns during falling-rate environments, according to the note.In addition, merger and acquisition activity remains healthy, with several $5 billion to $10 billion deals recently announced, including AbbVie (ABBV) purchasing Apogee (APGE), and Vertex Pharmaceuticals (VRTX) buying Crinetics Pharmaceuticals (CRNX), the investment bank said.Morgan Stanley adjusted its price targets on Biogen (BIIB) to $222 from $224, Amgen (AMGN) to $333 from $340, Gilead Sciences (GILD) to $166 from $168, AbbVie to $279 from $278, Moderna (MRNA) to $39 from $33, BioNTech (BNTX) to $119 from $126, Regeneron Pharmaceuticals (REGN) to $730 from $788, Johnson & Johnson (JNJ) to $284 from $283, and Eli Lilly (LLY) to $1,347 from $1,344.Shares of Biogen, Amgen, Gilead, AbbVie, Moderna, BioNTech, Regeneron, Johnson & Johnson, and Eli Lilly were down 2%, 0.1%, 0.8%, 0.4%, 7%, 1.9%, 1.9%, 0.4%, and 0.5% respectively, in Wednesday trading.Price: $201.67, Change: $-4.03, Percent Change: -1.96%
Andrew D Dickinson, Chief Financial Officer, on June 15, 2026, sold 3,000 shares in Gilead Sciences (GILD) for $376,200. Following the Form 4 filing with the SEC, Dickinson has control over a total of 171,646 common shares of the company, with 171,646 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/882095/000131020426000020/xslF345X05/wk-form4_1781646803.xml
Gilead Sciences (GILD) faces a potential threat from in vivo CAR-T, an early-stage technology that could transform the cell therapy space and impact 10% to 15% of Gilead's future revenue, RBC Capital Markets said Monday.Analysts expect Gilead's ex vivo CAR-T franchise to become an increasingly meaningful revenue driver. Its commercial Yescarta/Tecartus cell therapy portfolio generated $1.8 billion in 2025, and despite headwinds from bispecific competition and challenges scaling beyond academic centers, a gradual recovery is expected as anito-cel launches and ramps, the firm said. Total cell therapy sales could potentially exceed $4 billion around the end of the decade, the brokerage said.While there is room for organic growth of the cell therapy franchise, management believes only 10% to 20% of patients are eligible to actually receive CAR-T, while in vivo cell therapy presents a better alternative, the brokerage added.The company's in vivo focused transactions include the Interius BioTherapeutics acquisition, bringing a lentiviral vector-based in vivo CAR-T platform with preclinical proof of concept data and intellectual property now integrated into Gilead, and the Pregene collaboration, a complementary in vivo vector delivery platform adding intellectual property breadth and a distinct design approach, according to the note.RBC kept a sector perform rating on Gilead Sciences with a price target of $122.Price: $128.63, Change: $-0.53, Percent Change: -0.41%
Daniel Patrick O'Day, Director, Chairman & Chief Executive Officer, on June 01, 2026, sold 15,000 shares in Gilead Sciences (GILD) for $1,971,847. Following the Form 4 filing with the SEC, O'Day has control over a total of 617,567 common shares of the company, with 617,567 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/882095/000163864326000022/xslF345X05/wk-form4_1780437841.xml
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.3%.The iShares Biotechnology ETF (IBB) was fractionally lower.In corporate news, Eli Lilly (LLY) shares rose 2.5% after it said Friday that a new analysis from two phase 3 trials showed that its GLP-1 pill Foundayo at all doses tested was linked to "clinically significant" weight loss in adults 65 years old and older with obesity or overweight.Novo Nordisk's (NVO) Ozempic and Eli Lilly's Mounjaro are being linked to better cancer outcomes in four new studies, The Wall Street Journal reported. The weight-loss and diabetes drugs suggest they could reduce tumor progression, lower overall chance of death, and avert the risk of developing breast cancer, the report said. Novo shares added 1%.Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer. Merck shares jumped 5.6%.Gilead Sciences (GILD) shares gained 2.9%. The company has received approval from the US Food and Drug Administration for Hepcludex to treat chronic hepatitis delta virus infection in adults without advanced liver scarring, or with compensated cirrhosis, the FDA said Friday.
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.3%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, Gilead Sciences (GILD) shares gained 2.9%. The company has received approval from the US Food and Drug Administration for Hepcludex to treat chronic hepatitis delta virus infection in adults without advanced liver scarring, or with compensated cirrhosis, the FDA said Friday.
Gilead Sciences (GILD) has received approval from the US Food and Drug Administration for Hepcludex to treat chronic hepatitis delta virus infection in adults without advanced liver scarring, or with compensated cirrhosis, the FDA said Friday.The therapy is the first FDA-approved treatment for chronic HDV infection, a serious condition that can cause liver fibrosis, liver cancer, liver failure, and even death, the regulator said.The efficacy of Hepcludex was shown in a phase 3 trial, it said.Shares were up over 2% in afternoon trading.Price: $133.74, Change: $+3.24, Percent Change: +2.48%
Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.6% higher and the iShares Biotechnology ETF (IBB) down 0.1%.Biogen (BIIB) and Denali Therapeutics (DNLI) are discontinuing further development of BIIB122 in idiopathic Parkinson's disease after a phase 2b study failed to meet its primary or secondary endpoints, the companies said. Biogen shares were down 1% and Denali Therapeutics stock lost more than 3% pre-bell.Medline (MDLN) shares were up more than 1% after the company priced its upsized secondary offering of about 72.6 million of its class A shares on behalf of certain selling stockholders at $37 apiece.Gilead Sciences (GILD) said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion supporting approval of Trodelvy as a first-line treatment for certain patients with metastatic triple-negative breast cancer. Gilead Sciences shares were 0.4% higher pre-bell.
Gilead Sciences (GILD) has completed its previously announced acquisition of Germany-based Tubulis, a biotechnology company developing antibody-drug conjugates or ADCs, for $3.15 billion, Gilead said Thursday.The transaction entitles Tubulis to up to $1.85 billion in contingent milestone payments, according to the statement.Tubulis will remain based in Munich, Germany to establish its ADC innovation center, Gilead said.Price: $130.53, Change: $-0.16, Percent Change: -0.12%
Johanna Mercier, Chief Commercial & Corporate Affairs Officer, on May 15, 2026, sold 28,000 shares in Gilead Sciences (GILD) for $3,676,199. Following the Form 4 filing with the SEC, Mercier has control over a total of 125,779 common shares of the company, with 125,779 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/882095/000178213526000016/xslF345X05/wk-form4_1779140737.xml
Gilead Sciences' (GILD) mid-stage trial results from its ulcerative colitis drug candidate, emvistegrast, are not expected to move the stock, RBC Capital Markets said in a note Monday.The outcome from the small molecule drug trial is expected shortly, the note said, adding that the competitive bar is high, and prior oral efforts have not looked great."Focus is likely to remain on Yeztugo/HIV/anito-cel nearterm, and a ph. II readout is unlikely to materially move the stock," the report said.The note said the drug candidate has some pharmacological advantages against others and favorable results could help its immunology and inflammation segment emerge as a potential new area of long-term growth generation.The report pointed to Eli Lilly's (LLY) recent EMERALD-2 phase 2b data that showed only modest efficacy.RBC kept its sector perform rating with a price target of $122.Price: $133.64, Change: $+2.31, Percent Change: +1.76%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $170 on a multiple of 17.0x our 2027 EPS estimate, above GILD's five-year historical forward P/E average of 10.2x, justified by its improving outlook, in our view. We adjust our 2026 view to a loss of 0.67 per share from an EPS of $8.79 to account for the acquired IPR&D charges related to the Arcellx, Ouro, and Tubulis transactions. We lower our 2027 EPS estimate to $9.98 from $10.19. GILD reported a strong Q1 2026, above expectations for both revenue and EPS. Total product sales rose 5% Y/Y to $6.9B, while sales excluding Veklury (Covid-19 treatment) grew 8% to $6.8B. This performance was supported by robust growth in the HIV franchise, particularly the exceptional launch of the PrEP drug Yeztugo, and strong sales from the oncology drug Trodelvy. We think GILD is making solid progress in its pipeline, which management describes as the strongest in its history, bolstered by the recent acquisitions of Arcellx and the pending acquisitions of Ouro Medicines and Tubulis.
Gilead Sciences (GILD) is seeing strong pre-exposure prophylaxis growth, although questions remain on long-term Yeztugo growth, with expectations for the drug potentially having "gotten ahead of themselves," RBC Capital Markets said in a note Thursday.The brokerage said regional use patterns in existing PrEP markets underscore the challenges Gilead may face in substantially expanding overall PrEP use over the long term, while persistence for Yeztugo "seems not to be as good as initially hoped."The HIV business remains solid, driven by strong US Descovy sales in Q1, and the company's $400 million increase to full-year sales guidance reflects confidence in the continued growth of the business, according to the note.RBC maintained a sector perform rating on the stock and lowered its price target to $122 from $123.Shares of Gilead Sciences were down 2.5% in Friday trading.Price: $130.71, Change: $-3.35, Percent Change: -2.50%
Gilead Sciences (GILD) has an average rating of overweight and mean price target of $160.68, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $130.50, Change: $-3.56, Percent Change: -2.66%
Gilead Sciences (GILD) raised Yeztugo guidance for 2026 to $1 billion from $800 million, which is "good enough" for the stock, since Q1 Yeztugo sales were in line with consensus but likely below investor expectations, Morgan Stanley said Friday.Gilead raised total product sales guidance to $30 billion to $30.4 billion from $29.6 billion to $30 billion previously, versus Morgan Stanley's estimate of $30.3 billion and consensus of $30.2 billion, according to the firm. This excludes unchanged Veklury sales of $600 million, the brokerage said.The company guided to non-GAAP loss per share of $0.65 to $1.05, down from the prior EPS forecast of $8.45 to $8.85, driven by in-process research and development expenses tied to recent acquisitions, the firm said. This compares with Morgan Stanley's $0.68 loss estimate and $8.55 EPS consensus, according to the note.Morgan Stanley kept an overweight rating on Gilead Sciences and lowered the price target to $168 from $175.Price: $131.19, Change: $-2.87, Percent Change: -2.14%
Gilead Sciences (GILD) has an average rating of overweight and mean price target of $160.68, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $131.21, Change: $-2.85, Percent Change: -2.13%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GILD delivered strong Q1 2026 results above expectations, with total revenues of $7.0B (+4% Y/Y) and non-GAAP EPS of $2.03 (+12% Y/Y), demonstrating robust momentum across its core HIV franchise. Product sales excluding Veklury grew 8% Y/Y to $6.8B, indicating solid underlying business performance despite the anticipated 52% decline in Veklury sales to $144M. The HIV franchise continued as GILD's primary growth engine with Q1 sales of $5.0B (+10% Y/Y), led by Biktarvy's $3.4B (+7% Y/Y) and Descovy's strong 38% Y/Y growth to $807M, while the successful Yeztugo launch contributed $166M. GILD raised full-year 2026 product sales guidance to $30.0B-$30.4B but sharply lowered its EPS guidance due to $11.5B acquired IPR&D charges from strategic acquisitions. We believe the company's strategic investments in pipeline expansion through the Arcellx, Ouro, and Tubulis transactions position GILD well for long-term growth despite near-term EPS headwinds from acquisition-related charges.
Showing 1-20 of 37
